Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02988843
Other study ID # 2015LS190
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date March 29, 2017
Est. completion date December 15, 2019

Study information

Verified date November 2020
Source Masonic Cancer Center, University of Minnesota
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-center phase II study of brentuximab vedotin in combination with bevacizumab for the treatment of refractory CD-30+ germ cell tumors (GCT) after disease progression on imaging and/or tumor marker progression documented by serially rising alpha-fetoprotein (AFP) or beta human chorionic gonadotropin (bHCG) measured on at least 2 consecutive visits and determined by treating physician to be clinically significant. Patients unable to receive 2nd line of platinum-based chemotherapy due to toxicity or refusal would also be eligible.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date December 15, 2019
Est. primary completion date December 15, 2019
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male, = 18 years of age - Diagnosis of CD-30 positive germ cell tumor. CD30 expression will be tested by immunohistochemistry (IHC) in archival or fresh tumor tissue as is routinely done for diagnosis. - Disease progression on imaging or tumor marker progression (clinical significance of tumor marker progression to be decided per the discretion of treating physician) after at least 2 lines of platinum-based chemotherapies unless patient is ineligible for further platinum based chemotherapy or refuses 2nd line platinum based chemotherapy due to toxicity. For primary mediastinal germ cell tumors, failure of first-line chemotherapy will be accepted. Prior high dose chemotherapy with hematopoietic stem cell rescue is allowed. Prior treatment with bevacizumab is allowed. - At least 3 weeks should have elapsed since the last treatment (e.g. chemotherapy, targeted small molecule therapy, immunotherapy or radiation) and must have recovered to grade 1 or better from the acute effects of prior therapy. - Presence of measurable disease according to RECIST 1.1 - ECOG performance status 0 or 1 - Adequate marrow and organ function within 28 days prior to study registration as defined below: - Leukocytes > 3,000/µL - ANC > 1500/µL - Hemoglobin = 9 g/dL, Note: Blood transfusion will be allowed for patients with hemoglobin < 9 g/dl and G-CSF is allowed for neutropenic patients at time of enrollment. - Platelets > 100,000/mm3 - Creatinine: =3mg/dl OR if serum creatinine > 3 mg/dl, estimated GFR >30 mL/min/1.73m2 - INR: <1.5 x institutional upper limit of normal OR < 3 if on warfarin or other anticoagulants. There should be no evidence of active bleeding while on anticoagulants. - Total bilirubin: = 2 x institutional upper limit of normal (ULN) - SGOT (AST) or SGPT (ALT): < 3 x institutional upper limit of normal (< 5 x ULN if liver metastases present) - Proteinuria: If patient has proteinuria, it should be <2+ (< 100 mg/dl or per institutional guidelines). If proteinuria is 2+ or greater (= 100 mg/dl per institutional guidelines), patients should undergo a 24- hour urine collection and 24 hour urinary protein should be less than < 2 grams. - Sexually active men with partners of women of childbearing potential must agree to practice effective methods of contraception during the study and for 6 months after the last treatment - Provide voluntary written consent and HIPAA authorization for release of personal health information, approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC) Exclusion Criteria: - Prior treatment with Brentuximab Vedotin. - Known active brain metastases and or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided brain metastases are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to study registration. This exception does not include carcinomatous meningitis, which is excluded regardless of clinical stability. - History of blood clots, pulmonary embolism, or deep vein thrombosis in previous 6 months unless controlled by anticoagulant treatment - Known history of HIV - Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected) - Received a live vaccine within 1 week prior to the first dose of study treatment - Has active autoimmune disease that required systemic treatment with use of disease modifying agents, corticosteroids or immunosuppressive drugs - Any clinically significant active infection that requires systemic treatment at the time of enrollment. - Known allergy to bevacizumab or brentuximab vedotin or any of its excipients - Patients who have congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, ventricular fibrillation, clinically significant bradycardia, advanced heart block or a history of acute myocardial infarction (MI) within 6 months of study registration - History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess in previous 6 months - Prior major surgery within the previous 28 days of study registration and/or presence of any non-healing wound, fracture, or ulcer. - Use of an investigational agent within the previous 28 days of study registration. - Poorly controlled hypertension [defined as systolic blood pressure (SBP) of =150 mmHg and/or diastolic blood pressure (DBP) of = 90mmHg]. Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study registration - Arterial thromboembolic events, including transient ischemic attack (TIA), cerebrovascular accident (CVA), unstable angina, or MI within 6 months of study registration - History of posterior reversible encephalopathy syndrome - Other malignancies unless the patient is considered to be disease-free and has completed therapy for the malignancy > than 6 months prior to study entry - Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures - Concurrent use of rifampin or ketoconazole

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Brentuximab Vedotin
Dose level 1: 1.8 mg/kg every 21 days (up to 180 mg) Dose level -1 :1.2 mg/kg every 21 days ( up to 120 mg)
Bevacizumab
15 mg/kg every 21 days

Locations

Country Name City State
United States University of Minnesota Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disease Response Rate as Defined by the RECIST 1.1 Criteria, Integrated With Tumor Marker Response. Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.
In addition to CT scan to assess for disease evaluation, whole body bone scans will be done for patients with known or suspected bone metastases to assess for bone lesions.
1 year
Secondary Number of Participants Experiencing Progression Free Survival Incidence of Progression-free survival - Number of patients who were alive and did not have disease progression 2 years
Secondary Number of Participants Who Were Alive at 2 Years - Overall Survival Number of participants who were alive at 2 years (Overall survival) 2 years
Secondary Number of Participants Experiencing Adverse Events (AE) and Severe Adverse Events (SAE) Safety/ toxicity of brentuximab vedotin, measured by incidence of AEs/SAEs 2 Years
See also
  Status Clinical Trial Phase
Recruiting NCT06133543 - Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer N/A
Terminated NCT00369291 - CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant Phase 1
Terminated NCT00198172 - Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors Phase 2
Recruiting NCT05874063 - Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors Phase 3
Completed NCT03194906 - Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors Phase 2
Completed NCT01466231 - Everolimus in Refractory Testicular Germ Cell Cancer Phase 2
Recruiting NCT04791228 - A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors Phase 2
Active, not recruiting NCT03418844 - Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy N/A
Recruiting NCT05889585 - Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated With High-dose Chemotherapy and Autologous Stem Cell Transplant
Recruiting NCT05394675 - A Study of DS-9606a in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT03067181 - Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Phase 3
Withdrawn NCT03960151 - Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy Phase 2
Active, not recruiting NCT03158064 - Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Phase 2
Completed NCT03950830 - Disulfiram and Cisplatin in Refractory TGCTs. Phase 2
Recruiting NCT00898755 - Collecting and Storing Tissue From Young Patients With Cancer
Recruiting NCT04804007 - Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT Phase 2
Recruiting NCT05259605 - Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
Active, not recruiting NCT03638167 - EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors Phase 1
Recruiting NCT04308330 - Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies Phase 1
Recruiting NCT06418789 - High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors Phase 2